Business
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced the results from the multinational phase 3 WU-KONG28 study showing that ZEGFROVY® (sunvozertinib) monotherapy demonstrated superior anti-tumor efficacy, compared to platinum-doublet chemotherapy, in untreated NSCLC patients with EGFR exon 20 insertion mutations (exon20ins). These data were presented as a Late-Breaking Abstract Oral Presentation (#LBA8500)
About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A
[{"type":"list","items":[{"val":[{"type":"text","content":"ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"WU-KONG28 is the first global randomized phase 3 study with positive results for an oral, chemo-free, targeted monotherapy regimen in first-line EGFR exon20ins NSCLC","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Late-breaking data were presented at the 2026 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine","length":133,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":456,"olType":false},{"type":"text","content":"SHANGHAI, May 29, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced the results from the multinational phase 3 WU-KONG28 study showing that ZEGFROVY® (sunvozertinib) monotherapy demonstrated superior anti-tumor efficacy, compared to platinum-doublet chemotherapy, in untreated NSCLC patients with EGFR exon 20 insertion mutations (exon20ins). These data were presented as a Late-Breaking Abstract Oral Presentation (#LBA8500) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine (The NEJM).","length":696,"tagName":"p"},{"type":"image","alt":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","displaySize":"","headline":null,"caption":"Dizal logo (PRNewsfoto/Dizal Pharmaceutical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":153,"url":"https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wsIhVBDeioPd1hfwbvilSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3MA--/https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd","width":400,"height":153},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/AzXZV2ckmwOiXZ0Kn3J9kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI0NQ--/https://media.zenfs.com/en/prnewswire.com/9e23c08c9c79c06f760f1f1494c86ccd","width":400,"height":153}},"href":"https://mma.prnewswire.com/media/2084187/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"As ...
More updates from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A